腾博会官网·[中国]-诚信为本,专业服务!

INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE, 2023

INTERIM DIVIDEND FOR 2023

VOLUNTARY ANNOUNCEMENT - ENTERING INTO EXCLUSIVE LICENSE AND COOPERATION AGREEMENT WITH INVENTISBIO

NOTIFICATION OF BOARD MEETING

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JULY 2023

VOLUNTARY ANNOUNCEMENT - "TRASTUZUMAB INJECTION" APPROVED FOR LAUNCH TO MARKET

NEXT DAY DISCLOSURE RETURN

VOLUNTARY ANNOUNCEMENT - F-STAR ENTERED INTO STRATEGIC COLLABORATION AND LICENCE AGREEMENT WITH TAKEDA TO DISCOVER AND DEVELOP NEXT-GENERATION MULTI-SPECIFIC ANTIBODIES